Dark

Check out our API

NAVB
NAVIDEA BIOPHARMS INC
stock OTC

Inactive

Oct 1, 2025

0.000100USD0.000%(0.000000)27,270

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 17, 2021

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

Dec 16, 2021

04:02PM EST Navidea Biopharmaceuticals Announces Launch Of Phase 3 Clinical Trial In Rheumatoid Arthritis Benzinga

Dec 15, 2021

04:04PM EST Navidea Biopharmaceuticals Completes Full Enrollment In Phase 2b Normative Database Study To Support Its Rheumatoid Arthritis Program Benzinga

04:02PM EST Navidea Biopharmaceuticals Terminates Purchase Agreement Of $25M Worth Of Stock Benzinga

04:02PM EST Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program Business Wire

04:01PM EST Navidea Biopharmaceuticals Terminates Stock Purchase Agreement Business Wire

Dec 13, 2021

08:33AM EST Navient Announces New $1B Buyback Benzinga

07:41AM EST Navidea Biopharmaceuticals Announces Third-Party Asset Valuation Of Tc99m Tilmanocept For Indications In Rheumatoid Arthritis; Co. Reports 'Under base-case assumptions that are discussed in the report, peak U.S. sales could reach $1B annually, and in the upside scenario peak could reach $1.8B' Benzinga

07:41AM EST Navidea Biopharmaceuticals Announces Third-Party Asset Valuation Of Tc99m Tilmanocept For Indications In Rheumatoid Arthritis Benzinga

Dec 9, 2021

04:01PM EST Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Business Wire

Nov 10, 2021

04:09PM EST Navidea Says Established Exec. Leadership Committee To Lead Search For CEO Replacement Benzinga

04:07PM EST Navidea Biopharmaceutical Q3 EPS $(0.08) Beats $(0.11) Estimate, Sales $96.00K Down From $268.39K YoY Benzinga

04:01PM EST Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results Business Wire

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 5, 2021

01:24PM EDT Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro Benzinga

Nov 3, 2021

04:02PM EDT Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update Business Wire

Oct 26, 2021

05:24PM EDT Navidea Biopharmaceuticals Announces Resignation Of Jed A. Latkin Benzinga

Oct 14, 2021

07:39AM EDT Navidea Biopharma Appoints Thomas Forest Farb-Horch And Agnieszka Winkler To Board RTTNews

07:30AM EDT Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors Business Wire

Sep 28, 2021

12:16PM EDT Looking Into Navidea Biopharmaceutical's Return On Capital Employed Benzinga

Sep 27, 2021

07:34AM EDT Navidea Biopharmaceuticals Appoints Michel Mikhail As Chief Regulatory Officer, Effective October 1 RTTNews

07:30AM EDT Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer Business Wire

Sep 17, 2021

07:30AM EDT Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Business Wire

Aug 11, 2021

04:07PM EDT Navidea Biopharmaceutical Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $261.05K Down From $271.10K YoY Benzinga

04:01PM EDT Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results Business Wire

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

07:30AM EDT Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update Business Wire

Jul 19, 2021

07:37AM EDT Navidea Reports First 110 Subjects Imaged In NAV3-35 Normative Database Phase 2b Study To Support Rheumatoid Arthritis RTTNews

07:31AM EDT Navidea Biopharmaceuticals Announces First 110 Subjects Imaged In NAV3-35 Normative Database Phase 2b Study To Support Rheumatoid Arthritis Indications Benzinga

Jul 15, 2021

07:55AM EDT Navidea Biopharmaceuticals Inc. (NAVB) said Thursday that the U.S. Food and Drug Administration has granted the company's request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the pivotal Phase 3 trial. The meeting will take place on September 1, 2021 through conference call. RTTNews

07:38AM EDT Navidea:FDA Grants End-of-Phase 2 Type B Meeting Request On Sept. 1 To Discuss Clinical Program In Rheumatoid Arthritis RTTNews

07:34AM EDT Navidea Biopharmaceuticals Announces End-Of-Phase 2 Type B Meeting Request Granted By FDA To Discuss Ongoing Clinical Program In Rheumatoid Arthritis Benzinga

Jun 24, 2021

07:00AM EDT Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty Business Wire

May 19, 2021

07:35AM EDT Navidea Biopharma Announces Issuance Of U.S. Patent For Diagnosis And Treatment Of Viral Infections RTTNews

07:31AM EDT Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections Benzinga

May 18, 2021

03:49PM EDT Navidea Biopharmaceuticals Granted U.S. Patent Titled 'Compounds and methods for diagnosis and treatment of viral infections' Benzinga

May 11, 2021

04:08PM EDT Navidea Biopharmaceutical Q1 EPS $(0.11) Misses $(0.08) Estimate, Sales $124.00K Down From $156.27K YoY Benzinga

04:03PM EDT Navidea Biopharmaceutical Q1 EPS $(0.11) Misses $(0.08) Estimate Benzinga

04:01PM EDT Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results Business Wire

12:47PM EDT Earnings Scheduled For May 11, 2021 Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

07:41AM EDT Navidea Biopharma Announces NIH Grant Award For Clinical Study Evaluating Tc99m Tilmanocept As Kidney Imaging Agent RTTNews

07:37AM EDT Navidea Biopharmaceuticals Announces NIH Grant Award To UC San Diego For Clinical Study Evaluating Tc99m Tilmanocept As A Kidney Imaging Agent; Size Not Disclosed Benzinga

07:30AM EDT Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent Business Wire

04:14AM EDT Earnings Scheduled For May 11, 2021 Benzinga

May 5, 2021

08:00AM EDT Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Business Wire

May 4, 2021

07:30AM EDT Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update Business Wire

Apr 15, 2021

07:33AM EDT Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium Benzinga

Apr 8, 2021

03:47PM EDT Navidea Bio World Intellectual Property Organization PatentScope Listing For Co.'s ' COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS' Benzinga

Mar 24, 2021

04:26PM EDT Navidea Biopharmaceutical Q4 EPS $(0.11) Beats $(0.12) Estimate, Sales $219.25K Miss $600.00K Estimate Benzinga

04:21PM EDT Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

04:29AM EDT Earnings Scheduled For March 24, 2021 Benzinga

Mar 17, 2021

04:15PM EDT Navidea Biopharma 8-K Shows Co. Has Been Engaged In Ongoing Litigation With Capital Royalty Partners II Related To Co.'s Claims 'that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms..' Benzinga

07:30AM EDT Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update Business Wire

Mar 2, 2021

04:01PM EST Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Business Wire

07:41AM EST Navidea Biopharmaceuticals Announces $5M Private Placement Of Series E Redeemable Convertible Preferred Stock With Existing Investor John K. Scott, Jr Benzinga

07:30AM EST Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor Business Wire

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

04:28PM EST Navidea Biopharmaceuticals Files For Mixed Shelf Of Up To $100M Benzinga

04:06PM EST Navidea Biopharmaceuticals Announces Submissions Of Formal Type B Meeting Request With FDA, Launch Of NAV3-32 Phase 2B Trial In Rheumatoid Arthritis Benzinga

04:05PM EST Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Business Wire

Jan 7, 2021

07:30AM EST Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021 Business Wire

Dec 28, 2020

07:32AM EST Navidea Appoints Malcolm Witter To Its Board RTTNews

07:30AM EST Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter Business Wire

Nov 13, 2020

08:41AM EST Yahoo Finance Trending Stocks For Friday, Nov. 13, 2020: LI, NIO, DKNG, FSLY, DIS, CSCO, SOLO, CBAT, FSR, WKHS, HOFV, BIGC, KCAC, FTCH, AYRO, KNDI, SAVA, UROV, SPI, VIPS, NIU, BOXL, NETE, NAVB, U, ZOM, VFF, FLGT, BYDDF Benzinga

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

04:03PM EST Navidea Biopharmaceutical Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $268.00K Beat $150.00K Estimate Benzinga

04:03PM EST Navidea Biopharma Reports Results From Added Patients For Ongoing Phase 2b Study In Rheumatoid Arthritis: 'Data Support Hypothesis that Tc99m Tilmanocept Imaging Can Provide Early Indicator of Treatment Response' Benzinga

04:02PM EST Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results Business Wire

04:01PM EST Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis Business Wire

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

04:01PM EST Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update Business Wire

Oct 22, 2020

07:30AM EDT Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable Business Wire

Oct 9, 2020

07:33AM EDT Navidea Biopharma Reports Abstract Accepted For Presentation At American College Of Rheumatology Meeting Nov. 9 Between 9-11 a.m. EDT Benzinga

07:30AM EDT Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting Business Wire

Sep 28, 2020

07:30AM EDT Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange Business Wire

Sep 8, 2020

04:05PM EDT Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire

Sep 2, 2020

04:05PM EDT Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation Business Wire

Aug 24, 2020

04:05PM EDT Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference Business Wire

Aug 17, 2020

07:24AM EDT HC Wainwright & Co. Maintains Buy on Navidea Biopharmaceutical, Raises Price Target to $8 Benzinga

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 13, 2020

04:12PM EDT Navidea Biopharmaceutical Q2 EPS $(0.11) Up From $(0.24) YoY, Sales $271.00K Beat $156.00K Estimate Benzinga

04:09PM EDT Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results Business Wire

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Aug 10, 2020

02:32PM EDT Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher Benzinga

12:20PM EDT Mid-Day Market Update: Crude Oil Rises 2%; Eastman Kodak Shares Plummet Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Mostly Higher; Marriott Misses Q2 Expectations Benzinga

09:22AM EDT Jubilant And Navidea Sign Binding MoU For Commercialization Partnership RTTNews

09:08AM EDT Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership Business Wire

07:58AM EDT Navidea Biopharmaceuticals Also Reports Company Secured $25M of Committed Financing Benzinga

07:46AM EDT Navidea Signs Binding MOU With Jubilant Draximage RTTNews

07:42AM EDT Navidea Biopharmaceuticals Signs Binding Framework For Commercialization Partnership With Jubilant Radiopharma Benzinga

Aug 6, 2020

04:15PM EDT Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update Business Wire

Share